Back to top

rsi: Archive

Zacks Equity Research

Down -26.32% in 4 Weeks, Here's Why Clover Health Investments (CLOV) Looks Ripe for a Turnaround

Clover Health Investments (CLOV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

CLOVNegative Net Change

Zacks Equity Research

After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)

Gossamer Bio (GOSS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

GOSSNegative Net Change

Zacks Equity Research

Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround

Agenus (AGEN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

AGENPositive Net Change

Zacks Equity Research

Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)

Evolus (EOLS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

EOLSPositive Net Change

Zacks Equity Research

Here's Why Tencent Music Entertainment Group (TME) is Poised for a Turnaround After Losing -12.04% in 4 Weeks

The heavy selling pressure might have exhausted for Tencent Music Entertainment Group (TME) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

TMEPositive Net Change

Zacks Equity Research

Down -25.82% in 4 Weeks, Here's Why Clover Health Investments (CLOV) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Clover Health Investments (CLOV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

CLOVNegative Net Change

Zacks Equity Research

After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)

The heavy selling pressure might have exhausted for Gossamer Bio (GOSS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

GOSSNegative Net Change

Zacks Equity Research

Down -10.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)

Novartis (NVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

NVSPositive Net Change

Zacks Equity Research

Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks

Inozyme Pharma (INZY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

INZYPositive Net Change

Zacks Equity Research

Down -11.04% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)

Pfizer (PFE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

PFEPositive Net Change

Zacks Equity Research

Down -25.1% in 4 Weeks, Here's Why Navitas Semiconductor (NVTS) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Navitas Semiconductor (NVTS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

NVTSPositive Net Change

Zacks Equity Research

Down -14.77% in 4 Weeks, Here's Why You Should You Buy the Dip in BRP (DOOO)

BRP (DOOO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

DOOOPositive Net Change

Zacks Equity Research

Down -9.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Novartis (NVS)

Novartis (NVS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

NVSPositive Net Change

Zacks Equity Research

Down -10.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Vox Royalty Corp. (VOXR)

Vox Royalty Corp. (VOXR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

VOXRNegative Net Change

Zacks Equity Research

Down -21.79% in 4 Weeks, Here's Why You Should You Buy the Dip in HUYA (HUYA)

The heavy selling pressure might have exhausted for HUYA (HUYA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

HUYAPositive Net Change

Zacks Equity Research

Down -9.77% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)

Pfizer (PFE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

PFEPositive Net Change

Zacks Equity Research

After Plunging -7.43% in 4 Weeks, Here's Why the Trend Might Reverse for Alamos Gold (AGI)

Alamos Gold (AGI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

AGINegative Net Change

Zacks Equity Research

After Plunging -13.88% in 4 Weeks, Here's Why the Trend Might Reverse for PDD Holdings Inc. Sponsored ADR (PDD)

PDD Holdings Inc. Sponsored ADR (PDD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

PDDPositive Net Change

Zacks Equity Research

Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a Turnaround

Sana (SANA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

SANAPositive Net Change

Zacks Equity Research

Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD)

Prelude Therapeutics (PRLD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

PRLDPositive Net Change

Zacks Equity Research

FuelCell Energy (FCEL) Loses -27.82% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for FuelCell Energy (FCEL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

FCELPositive Net Change

Zacks Equity Research

After Plunging -22.76% in 4 Weeks, Here's Why the Trend Might Reverse for Bluebird (BLUE)

The heavy selling pressure might have exhausted for Bluebird (BLUE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

BLUENegative Net Change

Zacks Equity Research

Down -6.21% in 4 Weeks, Here's Why You Should You Buy the Dip in ING (ING)

ING (ING) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

INGPositive Net Change

Zacks Equity Research

Down -5.37% in 4 Weeks, Here's Why DTE Energy (DTE) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for DTE Energy (DTE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

DTENegative Net Change

Zacks Equity Research

Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)

The heavy selling pressure might have exhausted for AnaptysBio (ANAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

ANABPositive Net Change